GlassScriptPhysician profile
Jon G Dipietro
NPI 1356365530
$6,185.80
in general payments reported to CMS, 2019-2025
38 companies · $51.00 in 2025
The $51.00 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,368 · 2020: $1,202 · 2021: $1,649 · 2022: $1,420 · 2023: $388 · 2024: $107 · 2025: $51.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,414.98 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,024.15 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $553.83 | 2019-2022 | |
| Pfizer INC. | $511.83 | 2019-2025 | |
| Lilly USA, LLC | $441.21 | 2019-2022 | |
| Abbott Laboratories | $275.77 | 2019-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $208.95 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.93 | 2019-2022 | |
| Astellas Pharma US INC | $156.22 | 2019-2021 | |
| Glaxosmithkline, LLC. | $135.90 | 2021-2023 | Trelegy Ellipta |
| Medtronic Vascular, INC. | $124.48 | 2020 | |
| Novartis Pharmaceuticals Corporation | $122.17 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.47 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.19 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $99.77 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $86.12 | 2019-2023 | |
| Biohaven Pharmaceuticals, INC. | $78.84 | 2021 | |
| Eisai INC. | $58.90 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $54.99 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.05 | 2022 | |
| Arbor Pharmaceuticals, INC. | $50.83 | 2019-2021 | |
| Medicure Pharma INC. | $36.13 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.48 | 2021 | |
| Esperion Therapeutics, INC. | $25.99 | 2020 | |
| Pbg Puerto Rico LLC | $25.35 | 2021 | |
| Allergan, INC. | $24.07 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $21.48 | 2022 | |
| Corcept Therapeutics | $20.88 | 2021 | |
| Dexcom, INC. | $20.16 | 2022 | |
| Hikma Pharmaceuticals USA | $18.65 | 2021 | |
| Eyevance Pharmaceuticals LLC | $18.65 | 2021 | |
| Boston Scientific Corporation | $17.87 | 2025 | Watchman Access System |
| Radius Health, INC. | $17.74 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.54 | 2022 | |
| Dynavax Technologies Corporation | $17.23 | 2021 | |
| Vivus LLC | $15.70 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.95 | 2022 | |
| Gilead Sciences, INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Dipietro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.